In a systematic review exploring targeted biomarkers for rTMS therapy [103], depression was associated with increased GABA and BDNF levels, chronic pain was associated with increased levels of b-endorphin, and post-stroke neurologic deficit associated with decreased BDNF levels. This evidence concerns the gene BDNF and depressive symptom measurement.